Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Consumers

Prezista label update includes 192-week safety, resistance and efficacy data

Updates to the Prezista (darunavir) package insert, specifically sections, 6 Adverse Reactions, 12.4 Microbiology, 14 Clinical Studies and were approved on October 19, 2011 to include results from the 192-week safety, resistance and efficacy data from study TMC114-C211, “A randomized, controlled, open-label Phase 3 trial comparing PREZISTA/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects.”

In addition section 5.3 Severe Skin Reactions now includes the following text about PREZISTA/ritonavir + raltegravir containing regimens.

Rash occurred more commonly in treatment-experienced subjects receiving regimens containing PREZISTA/ritonavir + raltegravir compared to subjects receiving PREZISTA/ritonavir without raltegravir or raltegravir without PREZISTA/ritonavir. However, rash that was considered drug related occurred at similar rates for all three groups. These rashes were mild to moderate in severity and did not limit therapy; there were no discontinuations due to rash.

Prezista is a product of Tibotec.

The complete revised label is available at Drugs@FDA

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

Page Last Updated: 08/21/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.